Cannabis Science Reports 'CBS This Morning' Interview; US Surgeon General Believes Medical Cannabis 'Can Be Helpful' and Suggests Federal Policy Should Be Driven by Scientific Data

COLORADO SPRINGS, Colo., Feb. 5, 2015 /PRNewswire/ -- Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, today applauds US Surgeon General Vivek Murphy who announced yesterday in an interview on 'CBS This Morning' that "we have some preliminary data showing that for certain medical conditions and symptoms that marijuana can be helpful."  Surgeon General Vivek also said that scientific data should drive federal medical cannabis policy, and he is "very interested to see where that data takes us."

"Surgeon General Murphy's statement speaks for itself:  medical cannabis is now solidly in the mainstream of medical research, as cannabis treatments undoubtedly demonstrate usefulness in treating various critical ailments," said Chad S. Johnson, Esq., Director, COO and General Counsel of Cannabis Science, Inc.  "The Surgeon General's public statement on CBS looks to be a long-awaited political and legal 'game changer' on the federal level for patients in need of cannabinoid medicine."

Please see Surgeon General Vivek's unprecedented remarks at the following link:  U.S. Surgeon General Backs Medical Marijuana.

To learn more about Cannabis Science, please see the Company's website and recent announcements at the following link:  www.cannabisscience.com.

About Cannabis Science, Inc.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science, Inc
Raymond C. Dabney
Director, President & CEO, Co-Founder
[email protected]
Tel: 1.310.650.3788

Chad S. Johnson, Esq.
Director, COO & General Counsel
www.cannabisscience.com
Tel: 1.888.889.0888

SOURCE Cannabis Science, Inc.

Related Links

http://www.cannabisscience.com